BioSpace News Archive

CareDx, Inc. announced that it has received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT interpretation software for use in patients who have received hematopoietic cell transplantation.

Dermavant Sciences announced that the U.S. Food and Drug Administration has approved VTAMA® cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults.

Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved the Company’s Abbreviated New Drug Application for Regadenoson injection, 0.08 mg/mL, 5mL Single Dose Pre-Filled Syringe.

CB Scientific. Inc., a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products and services, announced that it has entered the regulatory testing phase for its updated myCam cardiac event monitoring device.

Electromedical Technologies, Inc. is pleased to provide its Financial and Operational Highlights for the three months ended March 31, 2022.

Affimed N.V. announced that its 2022 Annual General Meeting of Shareholders will be held on June 22, 2022 at 09:00 a.m. CET at the Radisson Blu Hotel, Amsterdam City Center, Rusland 17, 1012 CK Amsterdam, the Netherlands.

Humanigen, Inc., a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced that Cameron Durrant, Chairman & CEO, will give a corporate presentation at 11:00am EDT at the H.C. Wainwright Global Investment Conference taking place in Miami, FL, May 23-26, 2022.

SpringWorks Therapeutics, Inc. announced positive topline results from the DeFi trial, a double-blind, placebo-controlled Phase 3 trial evaluating the efficacy, safety and tolerability of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors.

Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation and a poster presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2022), being held May 31 – June 3, 2022, in Scottsdale, Ariz.

nSyneos Health®, the only fully integrated biopharmaceutical solutions organization, announced that the Company is scheduled to present at two upcoming investor conferences.